- VERAXA Biotech and Voyager Acquisition Corp. (NASDAQ: VACH) file Form F-4 with SEC for proposed merger.
- The transaction values VERAXA's equity contribution at $1.3 billion, anticipating a pro forma equity value of $1.64 billion at closing.
- The merger is expected to close in Q4 2025, contingent on shareholder approval and standard closing conditions.
VERAXA Biotech AG and Voyager Acquisition Corp. (VACH, Financial) have filed a Form F-4 Registration Statement with the U.S. Securities and Exchange Commission (SEC) as part of their business combination process. This move is a significant step towards creating a publicly traded biopharmaceutical entity specializing in next-generation cancer therapies.
The transaction places VERAXA's equity value at approximately $1.3 billion, with existing shareholders set to receive 130 million ordinary shares in the new entity. The combined company is projected to have a pro forma equity value of around $1.64 billion upon completion, benefiting from up to $253 million in cash held in trust by Voyager, assuming there are no shareholder redemptions.
Both VERAXA and Voyager’s boards have unanimously approved the merger, which is scheduled to be finalized by the fourth quarter of 2025. The completion of the merger is subject to regulatory approvals, shareholder consent, and other customary closing conditions.
The merger seeks to leverage VERAXA’s advancements in antibody-based therapeutics, including its proprietary BiTAC technology. This capital influx is expected to accelerate research and development activities, potentially expediting the clinical trials of its innovative cancer treatment pipeline.
